(Q68751609)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

title

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

main subject

phase II clinical trial

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

author name string

H S Hochster

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

M D Green

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

R H Blum

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

J C Wernz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

J L Speyer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

publication date

1 January 1986

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

27 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

page(s)

275-278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer

27 September 2019

cites work

1 reference

12 December 2020

Antileukemic activity of 4-demethoxydaunorubicin in mice

1 reference

12 December 2020

Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia

1 reference

12 December 2020

Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses

1 reference

12 December 2020

4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.

1 reference

12 December 2020

Comparison of Biochemical and Biological Methods in the Evaluation of New Anthracycline Drugs

1 reference

12 December 2020

Antitumor activity of 4-demethoxydaunorubicin administered orally

1 reference

12 December 2020

Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00179596

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3469171%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

1 reference